Editorials

Why Do Patients With Systemic Lupus Erythematosus Suffer Pain?
Anisur Rahman .......................................................... 1195

Transition Between Treatments: What We Need to Know
Kirsten Minden, Jens Klotsche ........................................ 1198

The COVID-19 Vaccine Landscape: What a Rheumatologist Needs to Know
Katie Bechman, Mrinalini Dey, Mark Yates, Marwan Bukhari, Kevin Winthrop, James B. Galloway ........................................... 1201

Rethinking Physical Activity Promotion During the COVID-19 Pandemic: Focus on a 24-hour Day
Linda C. Li, Lynne M. Feehan, Alison M. Hoens ........................... 1205

Review

Nail Psoriasis: Diagnosis, Assessment, Treatment Options, and Unmet Clinical Needs
Gurjit S. Kaeley, Lihi Eder, Sibel Zehra Aydin, Phoebe Rich, Catherine J. Bakewell ................................................................. 1208

Rheumatoid Arthritis

Impact of Comorbid Conditions on Healthcare Expenditure and Work-related Outcomes in Patients With Rheumatoid Arthritis
Martin Vu, Natalie Carvalho, Philip M. Clarke, Rachelle Buchbinder, An Tran-Duy ................................................................. 1221

Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs
Arthur Kavanaugh, Rene R. Westhovens, Kevin L. Winthrop, et al ................................................................. 1230

Meaningful Change Thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue and Pain Interference Scores in Patients With Rheumatoid Arthritis
Jennifer L. Beaumont, Elizabeth S. Davis, Jeffrey R. Curtis, David Cella, Huifeng Yun ................................................................. 1239

Open Access article

Tuberculosis in Biologic-naïve Patients With Rheumatoid Arthritis: Risk Factors and Tuberculosis Characteristics
Johanna Karlsson Sundbaum, Elizabeth V. Arkema, Judith Bruchfeld, Jerker Jonsson, Johan Askling, Eva Baecklund ................................................................. 1243

Spondyloarthritis

Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies
Georg Schett, Xenofon Baraliakos, Filip Van den Bosch, et al ................................................................. 1251

A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis
Peter C. Taylor, Désirée van der Heijde, Robert Landewé, Shannon McCue, Sue Cheng, Annelies Boonen ................................................................. 1259

Psoriatic Arthritis

Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire
Philip S. Helliwell, William Tillett, Robin Waxman, et al, on behalf of the PROMPT Study Group ................................................................. 1268

Comparison of Composite Measure Remission Targets in Psoriatic Arthritis
Flora Farkas, Natsumi Ikumi, Musaab Elmamoun, Agnes Szentpetery, Oliver FitzGerald ................................................................. 1272

Systemic Lupus Erythematosus

The Problem of Pain in Systemic Lupus Erythematosus: An Explication of the Role of Biopsychosocial Mechanisms
Titilola Falasinnu, Cristina Drenkard, Gaobin Bao, Sean Mackey, S. Sam Lim ................................................................. 1279

Sjögren Syndrome

Correlation Between Subjective and Objective Severity of Oral and Ocular Dryness in Primary Sjögren Syndrome
David A. Ripsman, Arthur A.M. Bookman ................................................................. 1290

Contents continued on page x